Actively Recruiting
Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults
Led by Scott Silveira · Updated on 2026-02-20
40
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
S
Scott Silveira
Lead Sponsor
C
Concordia University Chicago
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of a patented age-reversal therapy called EGA4 and conventional nicotinamide mononucleotide (NMN) supplementation on exercise tolerance and aging biomarkers in healthy adults aged 60 to 80 years. This randomized, double-blind, placebo-controlled, two-arm crossover clinical trial aims to assess safety and physiological activity of these treatments under controlled exercise conditions. The study focuses on improving physical performance and modulating metabolic markers related to aging. Participants will receive either EGA4, a proprietary combination of NMN, betaine, and low-dose hydrogen peroxide, or conventional NMN supplementation. Both interventions are given orally twice daily at a dose of 1000 mg NMN per day, with a placebo period between treatment phases to allow washout. The trial is designed with multiple arms where participants crossover between treatment and placebo, each intervention lasting four weeks. During the study, participants will attend at least four in-person laboratory visits where exercise tests such as constant work rate cycle ergometry will measure time to fatigue. Additional assessments include peak oxygen consumption, lactate threshold, anaerobic work capacity, critical power, and blood tests for NAD+ metabolites. Researchers will monitor adherence, safety, and physiological responses throughout the trial, which aims to provide data to inform future clinical evaluations of EGA4.
CONDITIONS
Brief Title
Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 60 to 80 years, of any sex
- Written clearance from primary care physician confirming medical fitness to participate in an exercise-based clinical study
- Normal or near-normal cardiovascular function confirmed by stress echocardiogram or coronary CT angiogram within past 12 months
- No new cardiovascular symptoms or health changes since cardiac testing
- Montreal Cognitive Assessment score of 26 or higher
- Free from acute or uncontrolled chronic medical conditions posing risk or interfering with participation
- Physically capable of moderate to vigorous stationary cycling exercise
- Successful completion of graded exercise test without adverse events
- Ability to attend at least four in-person laboratory visits
- Non-smoker for at least 12 months
- Able to provide informed consent and comply with procedures
- Willing to avoid new exercise, supplement, or medication regimens during study
You will not qualify if you...
- Severe cardiovascular disease such as recent myocardial infarction within 6 months, unstable angina, or uncontrolled hypertension above 160/100 mmHg
- Severe respiratory diseases preventing exercise participation
- Significant neurological impairments affecting comprehension or exercise participation
- Terminal illness or limited life expectancy
- Severe cognitive impairment preventing informed consent or protocol adherence
- Significant orthopedic limitations preventing safe exercise
- Use of NMN, NR, or other NAD+-altering supplements in past 14 weeks
- Alcohol consumption over 2 drinks per week or unwillingness to abstain during study
- Current substance abuse affecting participation
- Other acute or chronic conditions posing risk or interfering with study objectives
- Non-compliance with study requirements or withdrawal of consent
- Any condition judged by investigator to interfere with participation or result interpretation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
At least 4 in-person laboratory visits for assessments including exercise testing and medical clearance
Duration - Two 4-week intervention periods with a washout in between
Participants take oral doses of either EGA® (a proprietary NMN formulation), conventional NMN supplement, or placebo twice daily during each intervention period. Each participant experiences two 4-week intervention periods separated by a washout.
Visits at the beginning and end of each 4-week intervention period for exercise testing and biomarker measurements
Trial Site Locations
Total: 1 location
1
Medical Office of Dr. Robert Huizenga MD
Beverly Hills, California, United States, 90210
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here